{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:43:28Z","timestamp":1790675008871,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":327,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.toxrep.2021.11.016","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T17:44:55Z","timestamp":1638207895000},"page":"1960-1969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-5669","authenticated-orcid":false,"given":"Claudia","family":"Th\u00e4te","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Woischwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-5557","authenticated-orcid":false,"given":"Gunda","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-1816","authenticated-orcid":false,"given":"Sonja","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Baumgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxrep.2021.11.016_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5030039","article-title":"Mesenchymal stromal cells: what is the mechanism in acute graft-versus-host disease?","volume":"5","author":"Dunavin","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2018.11.007","article-title":"Response to nature commentary \"clear up this stem-cell mess\"","volume":"21","author":"Galipeau","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3324\/haematol.2015.140368","article-title":"Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease a multicenter survey","volume":"101","author":"Kuci","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/rme.11.105","article-title":"Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development","volume":"7","author":"Carmen","year":"2012","journal-title":"Regen. Med."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2012.48.12.1885866","article-title":"Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease","volume":"48","author":"Daly","year":"2012","journal-title":"Drugs Today"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0035","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","article-title":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)","volume":"53","author":"Bader","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0040","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0045","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.4049\/jimmunol.166.3.2133","article-title":"Innate and adaptive immune responses to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection","volume":"166","author":"Fox","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0050","first-page":"223","article-title":"Prioritizing therapeutic targets using patient-derived xenograft models","volume":"1855","author":"Lodhia","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0060","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/sj.bjc.6600573","article-title":"Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems","volume":"87","author":"Becker","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.imlet.2015.06.013","article-title":"Mesenchymal stromal cells and hematopoietic stem cell transplantation","volume":"168","author":"Bernardo","year":"2015","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular mesenchymal stromal\/stem cell therapy product diversification: time for new clinical guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2019.05.004","article-title":"Dissecting the pharmacodynamics and pharmacokinetics of MSCs to overcome limitations in their clinical translation","volume":"14","author":"Salvadori","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/sctm.17-0209","article-title":"Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem\/stromal cells","volume":"7","author":"Brooks","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.TP.0000128334.93343.B3","article-title":"Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice","volume":"78","author":"Allers","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0090","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.12553","article-title":"Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model","volume":"93","author":"Kyriakou","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fimmu.2012.00297","article-title":"Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion","volume":"3","author":"Eggenhofer","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0100","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ymthe.2004.02.022","article-title":"The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: implications for skeletal gene therapy via stem cells","volume":"9","author":"Niyibizi","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000047856","article-title":"The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion","volume":"169","author":"Gao","year":"2001","journal-title":"Cells Tissues Organs (Print)"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00725-7","article-title":"Mesenchymal stem\/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications","volume":"28","author":"Zhuang","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0115","first-page":"FF01","article-title":"Safety assessment of human bone marrow-derived mesenchymal stromal cells transplantation in Wistar rats","volume":"11","author":"Aithal","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0120","doi-asserted-by":"crossref","first-page":"852","DOI":"10.4103\/ijmr.IJMR_1842_15","article-title":"Preclinical safety & toxicity evaluation of pooled, allogeneic human bone marrow-derived mesenchymal stromal cells","volume":"144","author":"Rengasamy","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000496809","article-title":"Clinical use of mesenchymal stromal cells in the treatment of acute graft-versus-host disease","volume":"46","author":"Elgaz","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0135","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/0300985817698210","article-title":"Pathology of aging in NOD scid gamma female mice","volume":"54","author":"Santagostino","year":"2017","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.toxrep.2021.11.016_bib0140","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/ijc.23772","article-title":"Human acute leukemia cells injected in NOD\/LtSz-scid\/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD\/scid-related strains","volume":"123","author":"Agliano","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0145","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.18632\/oncotarget.27001","article-title":"Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall","volume":"10","author":"Moyer","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.toxrep.2021.11.016_bib0150","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcyt.2018.12.005","article-title":"In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials","volume":"21","author":"Tappenbeck","year":"2019","journal-title":"Cytotherapy"}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750021002006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750021002006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:52:18Z","timestamp":1780415538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750021002006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":30,"alternative-id":["S2214750021002006"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2021.11.016","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2021.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}